Journal: bioRxiv
Article Title: Increases in BCL2L1 and ID1 dosage synergistically drive fate bias and competitive advantage in human pluripotent stem cells
doi: 10.64898/2026.03.26.714405
Figure Lengend Snippet: Effects of BCL2L1 and ID1 overexpression on hESC differentiation. (B) Quantitative RT-PCR analysis of BCL2L1 and ID1 expression levels in WT, 20q gain, and hESC lines overexpressing BCL2L1, ID1, or both (BCL2L1/ID1). (C) Immunofluorescence staining of the VUB03 cell line: WT, 20q gain, BCL2L1-OE, ID1-OE, and double (BCL2L1 + ID1) overexpression lines. The final condition represents wild-type cells treated with SB and BMP4. Stained markers include PAX6 (yellow; neuroectoderm, panel 1), TFAP2A (magenta; surface ectoderm, panel 2), KRT8 (turquoise; surface ectoderm, panel 2), EPCAM (turquoise; surface ectoderm, panel 3), and OCT4 (magenta; pluripotency, panel 3). (D) Quantification of neuroectoderm immunostaining of BCL2L1-OE, ID1-OE, and double (BCL2L1 + ID1) overexpression lines showing marker intensity similar to . (E) Immunofluorescence staining of VUB03 cells after 14 days of spontaneous differentiation. Stained markers include PAX6 (yellow; neuroectoderm, panel 1), TFAP2A (magenta; surface ectoderm, panel 2), OCT4 (turquoise; pluripotency, panel 2), EPCAM (turquoise; surface ectoderm, panel 3), and KRT8 (magenta; surface ectoderm, panel 3). (F) Quantification of immunostaining of BCL2L1-OE, ID1-OE, and double (BCL2L1 + ID1) overexpression lines after spontaneous differentiation showing marker intensity similar to . (G) Fraction of marker-positive cells after 8 days of neuroectoderm differentiation. (H) Fraction of marker-positive cells after 14 days of spontaneous differentiation.
Article Snippet: The ID1 expression plasmid (TFORF2860) was obtained from Addgene (plasmid #143643), with ID1 expression driven by the EF-1α promoter.
Techniques: Over Expression, Quantitative RT-PCR, Expressing, Immunofluorescence, Staining, Immunostaining, Marker